By Brazil Stock Guide – The acquisition of Hospital Santa Catarina by Unimed Blumenau, which controls about 84% of the local medical health plan market, has entered the toughest phase of Brazil’s antitrust review. The General Superintendence of Cade, Brazil’s antitrust regulator, challenged the deal and recommended its rejection, saying the transaction could give the city’s dominant health plan operator control over an essential hospital asset and weaken competitors in two markets at once: health plans and hospital services.
The decision is not final. The case will now be reviewed by Cade’s Tribunal, which may block the deal, approve it with restrictions or clear the transaction. Still, the technical recommendation raises the regulatory risk around the acquisition and turns the case into an important test for vertical integration in Brazil’s private healthcare industry.
The key issue is scale. According to Cade’s economic analysis, Unimed Blumenau had about 81% of the medical health plan market in Blumenau in 2023 and reached roughly 84% by the end of 2025. In terms of covered lives, the operator peaked at 97,953 beneficiaries in April 2024 and has since remained around 97,000 beneficiaries.
Dominant operator
For its competition analysis, Cade focused on Blumenau, where the combination of a highly concentrated health plan market and hospital control raised concerns.
Hospital Santa Catarina is not a marginal asset. It is a private general hospital offering inpatient care, surgery, emergency services and outpatient treatment. The hospital has 160 beds in its overall structure, including 16 intensive care beds, eight of them linked to Brazil’s public health system. By revenue, its share of the general hospital market analyzed by Cade rose from 67.1% in 2023 to 73.1% in 2025.
For Cade’s technical staff, that combination creates incentives for market foreclosure. In practice, Unimed could steer patients to its own hospital, reduce demand for competing hospitals or make rival health plans less attractive if they depend on access to Hospital Santa Catarina.
Network as barrier
Cade’s Department of Economic Studies identified risks in two directions. On one side, Unimed could restrict demand for competing hospitals. Hospital Santa Isabel, the main rival to Hospital Santa Catarina, saw its share of non-public health system beds fall from 39.3% in 2023 to 36.7% in 2024 and 2025. Using revenue as the metric, Cade also identified foreclosure incentives against Hospital Santo Antônio, described as HSC’s second-largest competitor.
On the other side, Hospital Santa Catarina, under Unimed’s control, could limit access by competing health plan operators, whether through delisting, higher prices, lower volumes or worse commercial terms. Cade’s economic department concluded that, in 2023, it could not rule out foreclosure incentives against the seven largest rival operators to Unimed Blumenau.
Clinipam in focus
The technical note includes a sensitive data point. Hapvida, through the Clinipam brand, saw its market share fall from about 11% in 2023 to around 5% by the end of 2025. Over the same period, Unimed’s share rose from about 81% to 84%.
Cade also noted that Clinipam informed its beneficiaries that Hospital Santa Catarina would leave its network as of June 20, 2023, citing reasons beyond its control. The authority stressed that the event took place before the transaction was completed and therefore cannot be directly attributed to the acquisition.
Even so, the episode reinforces the hospital’s competitive importance. For a rival health plan operator, losing access to Hospital Santa Catarina can mean losing the ability to sell attractive plans in Blumenau.
Sensitive history
The case also carries a sensitive procedural history. In October 2025, Cade’s Tribunal ordered the transaction to be formally notified within 30 days after concluding that the acquisition had been completed before antitrust review.
The proceeding began with a complaint submitted through Cade’s whistleblower channel in May 2024. After a request for clarification, Hospital Santa Catarina told Cade that the deal had been formalized on May 24, 2024, confirming that the transaction had taken place.
Before that, Cade counselor Victor Oliveira Fernandes had granted a precautionary measure to preserve competitive conditions in the sector. The decision required non-discriminatory maintenance of hospital service contracts and accreditations, as well as the reinstatement of medical, hospital, clinical or laboratory providers that may have been removed because of the transaction while the merger review was still pending.
Weak remedies
The General Superintendence also rejected the idea that behavioral remedies would be enough. For Cade’s technical staff, obligations to contract, non-discrimination commitments or rules to maintain accreditations would require permanent monitoring and would not restore the competitive conditions that existed before the deal.
Since July 2025, the competitive dynamics have been shaped by Cade’s precautionary measure, which may have limited, mitigated or discouraged foreclosure conduct. In other words, the absence of new delistings does not eliminate the risk. It may simply show that the authority had already blocked part of the potentially problematic behavior.
Sector test
The decision will be a test for vertical integration in Brazil’s private healthcare market. When a dominant health plan operator buys an essential hospital, operational efficiency and market foreclosure become almost the same debate.
Leave a Reply